HBsAg-vectored vaccines simultaneously deliver CTL responses to protective epitopes from multiple viral pathogens.

[1]  C. Ottensmeier,et al.  DNA vaccines: precision tools for activating effective immunity against cancer , 2008, Nature Reviews Cancer.

[2]  Bjoern Peters,et al.  HLA class I supertypes: a revised and updated classification , 2008, BMC Immunology.

[3]  R. Tindle,et al.  Multiple copies of a tumor epitope in a recombinant hepatitis B surface antigen (HBsAg) vaccine enhance CTL responses, but not tumor protection. , 2007, Virology.

[4]  A. Rickinson,et al.  Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. , 2007, Annual review of immunology.

[5]  S. Wain-Hobson,et al.  Optimisation of secretion of recombinant HBsAg virus-like particles: Impact on the development of HIV-1/HBV bivalent vaccines. , 2007, Vaccine.

[6]  H. Netter,et al.  Hepatitis B Surface Antigen Vector Delivers Protective Cytotoxic T-Lymphocyte Responses to Disease-Relevant Foreign Epitopes , 2006, Journal of Virology.

[7]  I. Mackay,et al.  Cytotoxic T-Lymphocyte Epitope Vaccination Protects against Human Metapneumovirus Infection and Disease in Mice , 2006, Journal of Virology.

[8]  Robert Y. L. Wang,et al.  Reduced Secretion of Virions and Hepatitis B Virus (HBV) Surface Antigen of a Naturally Occurring HBV Variant Correlates with the Accumulation of the Small S Envelope Protein in the Endoplasmic Reticulum and Golgi Apparatus , 2005, Journal of Virology.

[9]  D. Fuller,et al.  Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device. , 2005, Vaccine.

[10]  I. Berkower,et al.  Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120. , 2004, Virology.

[11]  R. Seder,et al.  DNA vaccination: the answer to stable, protective T-cell memory? , 2003, Current opinion in immunology.

[12]  Harald zur Hausen,et al.  A Synthetic E7 Gene of Human Papillomavirus Type 16 That Yields Enhanced Expression of the Protein in Mammalian Cells and Is Useful for DNA Immunization Studies , 2003, Journal of Virology.

[13]  M. Raje,et al.  Recombinant dengue virus type 2 envelope/hepatitis B surface antigen hybrid protein expressed in Pichia pastoris can function as a bivalent immunogen. , 2002, Journal of biotechnology.

[14]  A. Hill,et al.  Role of transfection in the priming of cytotoxic T-cells by DNA-mediated immunization. , 2002, Vaccine.

[15]  G. Gao,et al.  Virus-specific CTL responses induced by an H-2K(d)-restricted, motif-negative 15-mer peptide from the fusion protein of respiratory syncytial virus. , 2002, The Journal of general virology.

[16]  A. Suhrbier,et al.  Cytotoxic T cell polyepitope vaccines delivered by ISCOMs. , 2001, Vaccine.

[17]  C Crimi,et al.  Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. , 2001, Vaccine.

[18]  Steven A. Rosenberg,et al.  Progress in human tumour immunology and immunotherapy , 2001, Nature.

[19]  T. Macnaughton,et al.  Antigenicity and Immunogenicity of Novel Chimeric Hepatitis B Surface Antigen Particles with Exposed Hepatitis C Virus Epitopes , 2001, Journal of Virology.

[20]  Mary S. Wu,et al.  Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. , 2000, Vaccine.

[21]  F. Lemonnier,et al.  Multiepitopic HLA-A*0201-Restricted Immune Response Against Hepatitis B Surface Antigen After DNA-Based Immunization , 2000, The Journal of Immunology.

[22]  P. Dellabona,et al.  Relevance of the Tumor Antigen in the Validation of Three Vaccination Strategies for Melanoma1 , 2000, The Journal of Immunology.

[23]  R. Offringa,et al.  Differential binding of viral peptides to HLA‐A2 alleles. Implications for human papillomavirus type 16 E7 peptide‐based vaccination against cervical carcinoma , 1999, European journal of immunology.

[24]  G Y Ishioka,et al.  Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. , 1999, Journal of immunology.

[25]  A. Fomsgaard,et al.  Improved immunogenicity of HIV-1 epitopes in HBsAg chimeric DNA vaccine plasmids by structural mutations of HBsAg. , 1999, DNA and cell biology.

[26]  P. Lambert,et al.  Mice expressing the E7 oncogene of HPV16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic T-lymphocyte epitopes. , 1998, Virology.

[27]  D. Chargelegue,et al.  A Peptide Mimic of a Protective Epitope of Respiratory Syncytial Virus Selected from a Combinatorial Library Induces Virus-Neutralizing Antibodies and Reduces Viral Load In Vivo , 1998, Journal of Virology.

[28]  D. Moss,et al.  Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. , 1998, Journal of immunology.

[29]  D. Chargelegue,et al.  Reduction of respiratory syncytial virus titer in the lungs of mice after intranasal immunization with a chimeric peptide consisting of a single CTL epitope linked to a fusion peptide. , 1998, Virology.

[30]  C. Leclerc,et al.  The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. , 1997, Cellular immunology.

[31]  X. Mo,et al.  Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. , 1996, Journal of immunology.

[32]  H. Davis,et al.  DNA-mediated immunization to hepatitis B surface antigen: longevity of primary response and effect of boost. , 1996, Vaccine.

[33]  J. Berzofsky,et al.  Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Reimann,et al.  DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein. , 1995, Human gene therapy.

[35]  F. Chisari,et al.  Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice , 1995, Journal of virology.

[36]  J. Bell,et al.  Selection of T cell receptor variable gene‐encoded amino acids on the third binding site loop: a factor influencing variable chain selection in a T cell response , 1995, European journal of immunology.

[37]  J. Reimann,et al.  Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo. , 1994, Journal of immunology.

[38]  F. Chisari,et al.  Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis , 1993, The Journal of experimental medicine.

[39]  M. Feltkamp,et al.  Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells , 1993, European journal of immunology.

[40]  P. Cresswell,et al.  Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I- restricted cell-mediated lysis , 1991, The Journal of experimental medicine.

[41]  D. Ganem,et al.  Mutational analysis of hepatitis B surface antigen particle assembly and secretion , 1991, Journal of virology.

[42]  A. Vitiello,et al.  Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex , 1991, The Journal of experimental medicine.

[43]  D. Gray,et al.  Novel pathways of antigen presentation for the maintenance of memory. , 1991, International immunology.

[44]  M. Perkins,et al.  Primary respiratory syncytial virus infection in mice , 1988, Journal of medical virology.

[45]  B A Askonas,et al.  Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus , 1988, The Journal of experimental medicine.

[46]  Howard M. Goodman,et al.  Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen , 1979, Nature.

[47]  F. Guarnieri,et al.  Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. , 1996, Cancer research.

[48]  R. Gupta,et al.  Adjuvants for human vaccines--current status, problems and future prospects. , 1995, Vaccine.